Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Cited In for PubMed (Select 20299055)

1.

Interest in genomic SNP testing for prostate cancer risk: a pilot survey.

Hall MJ, Ruth KJ, Chen DY, Gross LM, Giri VN.

Hered Cancer Clin Pract. 2015 Apr 8;13(1):11. doi: 10.1186/s13053-015-0032-3. eCollection 2015.

2.

Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008.

Cook MB, Rosenberg PS, McCarty FA, Wu M, King J, Eheman C, Anderson WF.

Prostate. 2015 May;75(7):758-63. doi: 10.1002/pros.22958. Epub 2015 Jan 25.

PMID:
25619191
3.

The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.

Jahn JL, Giovannucci EL, Stampfer MJ.

Int J Cancer. 2014 Dec 29. doi: 10.1002/ijc.29408. [Epub ahead of print]

PMID:
25557753
4.

Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.

Moses KA, Chen LY, Sjoberg DD, Bernstein M, Touijer KA.

BMC Urol. 2014 Dec 11;14:98. doi: 10.1186/1471-2490-14-98.

5.

Reclassification rates are higher among African American men than Caucasians on active surveillance.

Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM.

Urology. 2015 Jan;85(1):155-60. doi: 10.1016/j.urology.2014.08.014. Epub 2014 Oct 14.

PMID:
25440814
6.

Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up.

Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, Ross AE, Schaeffer EM.

Urology. 2014 Dec;84(6):1434-41. doi: 10.1016/j.urology.2014.08.039.

7.

Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Canadian Task Force on Preventive Health Care, Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, Shaw E, Dunfield L, Tonelli M.

CMAJ. 2014 Nov 4;186(16):1225-34. doi: 10.1503/cmaj.140703. Epub 2014 Oct 27. No abstract available.

PMID:
25349003
8.

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Levin AM, Lindquist KJ, Avila A, Witte JS, Paris PL, Rybicki BA.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1677-82. doi: 10.1158/1055-9965.EPI-13-1124. Epub 2014 Jun 2.

PMID:
24891551
9.

Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S.

Lancet Oncol. 2014 May;15(6):e234-42. doi: 10.1016/S1470-2045(13)70598-9.

10.

Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1505-11. doi: 10.1158/1055-9965.EPI-13-1328. Epub 2014 May 6.

PMID:
24802741
11.

Clinical presentation of prostate cancer in black South Africans.

Tindall EA, Monare LR, Petersen DC, van Zyl S, Hardie RA, Segone AM, Venter PA, Bornman MS, Hayes VM.

Prostate. 2014 Jun;74(8):880-91. doi: 10.1002/pros.22806. Epub 2014 Apr 9.

12.

Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention.

Kumar N, Chornokur G.

Transl Med (Sunnyvale). 2012 Dec 31;Suppl 2:005.

13.

MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Sutcliffe S, De Marzo AM, Sfanos KS, Laurence M.

Prostate. 2014 May;74(6):569-78. doi: 10.1002/pros.22778. Epub 2014 Jan 24. Review.

14.

Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer.

Handorf E, Crumpler N, Gross L, Giri VN.

J Genet Couns. 2014 Jun;23(3):371-6. doi: 10.1007/s10897-013-9672-5. Epub 2013 Dec 7.

15.

Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida.

Xiao H, Tan F, Goovaerts P, Ali A, Adunlin G, Gwede CK, Huang Y.

Am J Mens Health. 2013 Dec 1;8(4):316-326. [Epub ahead of print]

16.

'Race' and prostate cancer mortality in equal-access healthcare systems.

Graham-Steed T, Uchio E, Wells CK, Aslan M, Ko J, Concato J.

Am J Med. 2013 Dec;126(12):1084-8. doi: 10.1016/j.amjmed.2013.08.012. Review.

17.

Opposing roles of folate in prostate cancer.

Rycyna KJ, Bacich DJ, O'Keefe DS.

Urology. 2013 Dec;82(6):1197-203. doi: 10.1016/j.urology.2013.07.012. Epub 2013 Aug 28. Review.

18.

Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.

Chang BL, Hughes L, Chen DY, Gross L, Ruth K, Giri VN.

BJU Int. 2014 May;113(5b):E150-6. doi: 10.1111/bju.12264. Epub 2013 Aug 13.

19.

Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Holly JM, Zeng L, Perks CM.

Cancer Metastasis Rev. 2013 Dec;32(3-4):673-705. doi: 10.1007/s10555-013-9445-5. Review.

20.

African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?

Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM.

J Clin Oncol. 2013 Aug 20;31(24):2991-7. doi: 10.1200/JCO.2012.47.0302. Epub 2013 Jun 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk